Loading ...
Sorry, an error occurred while loading the content.
 

Phase 3 ZADAXIN Hepatitis C Triple Therapy Trial

Expand Messages
  • Shshonee (Alley)
    SciClone s European Partner Sigma-Tau Initiates Phase 3 ZADAXIN Hepatitis C Triple Therapy Trial; First Patients Business Wire Thu, 23 Dec 2004 3:43 AM PST SAN
    Message 1 of 1 , Dec 23 10:58 AM
      SciClone's European Partner Sigma-Tau Initiates Phase 3 ZADAXIN Hepatitis C Triple Therapy Trial; First Patients
      Business Wire Thu, 23 Dec 2004 3:43 AM PST
      SAN MATEO, Calif.--(BUSINESS WIRE)--Dec. 23, 2004--SciClone Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced that Sigma-Tau, its European development and marketing partner for ZADAXIN(R), has begun enrolling patients infected with the hepatitis C virus (HCV) in a multi-center European phase 3 clinical trial evaluating the triple therapy combination of ZADAXIN, pegylated interferon alpha and
      http://home.businesswire.com/portal/site/altavista/index.jsp?ndmViewId=news_view&newsId=20041223005058&newsLang=en

      [Non-text portions of this message have been removed]
    Your message has been successfully submitted and would be delivered to recipients shortly.